New

HDAC Inhibitor Market

2021

HDAC Inhibitor Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Class I HDACs, Class II HDACs, Class III HDACs, Class IV HDACs); Applications (Oncology, Neurology, Others); End User (Hospitals, Oncology Clinics, Others.) and Geography

| Report Code: TIPRE00023439 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming

Market Insights

HDAC Inhibitor Market 2028 By Class, Applications, End User and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Histone deacetylase inhibitors (HDAC) are chemical compounds that inhibit the activity of HDAC enzymes. They help the body's immune cells to recognize and attack tumor cells. HDAC inhibitors are a new class of anti-cancer agents and are widely used in the diagnosis, treatment, and prognosis of cancer. They are used as mood stabilizers and anti-epileptics in psychiatry and neurology. They are considered a treatment option for hematological malignancies and play an important role in epigenetic or non-epigenetic regulation. There are about 18 known human HDACs, and based on their structures, they are classified into four classes.

MARKET SCOPE

The "Global HDAC Inhibitor Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the HDAC inhibitor market with detailed market segmentation by class, application, end user, and geography. The report provides key statistics on the market status of the leading HDAC inhibitor market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •  Based on class, the global HDAC inhibitor market is segmented into class I HDACs, class II HDACs, class III HDACs and class IV HDACs.
  •  On the basis of application, the market is bifurcated into oncology, neurology and others.
  •  On the basis of end-users, the market is bifurcated into hospitals, oncology clinics and others.

MARKET DYNAMICS
Drivers

  •  The increasing prevalence of cancer and various chronic diseases, high unmet needs in the treatment landscape, and rising demand for histone deacetylase inhibitors drive the HDAC inhibitor market.
  •  Rapid technological advancements and increasing R&D activities for cancer fuel market growth.
  •  Growing collaborations and investments in manufacturing and the growing need for innovative medications and improved therapies for cancer treatment boost market growth.

Restraints

  •  The unfavorable reimbursement policies.
  •  Lack of skilled professionals in developing economies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The HDAC inhibitor market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the HDAC inhibitor market in these regions.

IMPACT OF COVID-19 ON HDAC INHIBITOR MARKET

COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The HDAC inhibitors are utilized by diabetic and kidney patients to fight the disease-causing cells. The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients suffering from Covid-19 infection to avoid acute respiratory syndrome. The valproic acid helps the person who is infected to decrease the respiratory distress syndrome along with other organ damage, reducing hospitalization. HDAC provides drugs that are used in treating the infectious virus. Hence, the demand has surged, resulting in the growth of the market. Early intervention with HDAC inhibitors addressing the secondary consequences of SARS-CoV-2 infection will help reduce complications and mortality and provide a better quality of life for COVID-19 recovered patients. Hence, the above-mentioned factors have significantly affected the market.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the HDAC inhibitor market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from HDAC inhibitor market are anticipated to have lucrative growth opportunities in the future with the rising demand for HDAC inhibitor in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the HDAC inhibitor market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Celleron Therapeutics
  •  Celgene Corporation
  •  Novartis
  •  Eisai Co., Ltd
  •  Merck & Co., Inc.
  •  Pfizer Inc.
  •  Acetylon Pharmaceuticals, Inc.
  •  AstraZeneca plc.
  •  Chipscreen Biosciences
  •  Chroma Therapeutics

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 HDAC Inhibitor Market - By Class
1.3.2 HDAC Inhibitor Market - By Applications
1.3.3 HDAC Inhibitor Market - By End User
1.3.4 HDAC Inhibitor Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. HDAC INHIBITOR MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. HDAC INHIBITOR MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. HDAC INHIBITOR MARKET - GLOBAL MARKET ANALYSIS
6.1. HDAC INHIBITOR - GLOBAL MARKET OVERVIEW
6.2. HDAC INHIBITOR - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING

7. HDAC INHIBITOR MARKET - REVENUE AND FORECASTS TO 2028 - CLASS
7.1. OVERVIEW
7.2. CLASS MARKET FORECASTS AND ANALYSIS
7.3. CLASS I HDACS
7.3.1. Overview
7.3.2. Class I HDACs Market Forecast and Analysis
7.4. CLASS II HDACS
7.4.1. Overview
7.4.2. Class II HDACs Market Forecast and Analysis
7.5. CLASS III HDACS
7.5.1. Overview
7.5.2. Class III HDACs Market Forecast and Analysis
7.6. CLASS IV HDACS
7.6.1. Overview
7.6.2. Class IV HDACs Market Forecast and Analysis
8. HDAC INHIBITOR MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATIONS
8.1. OVERVIEW
8.2. APPLICATIONS MARKET FORECASTS AND ANALYSIS
8.3. ONCOLOGY
8.3.1. Overview
8.3.2. Oncology Market Forecast and Analysis
8.4. NEUROLOGY
8.4.1. Overview
8.4.2. Neurology Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. HDAC INHIBITOR MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. ONCOLOGY CLINICS
9.4.1. Overview
9.4.2. Oncology Clinics Market Forecast and Analysis
9.5. OTHERS.
9.5.1. Overview
9.5.2. Others. Market Forecast and Analysis

10. HDAC INHIBITOR MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America HDAC Inhibitor Market Overview
10.1.2 North America HDAC Inhibitor Market Forecasts and Analysis
10.1.3 North America HDAC Inhibitor Market Forecasts and Analysis - By Class
10.1.4 North America HDAC Inhibitor Market Forecasts and Analysis - By Applications
10.1.5 North America HDAC Inhibitor Market Forecasts and Analysis - By End User
10.1.6 North America HDAC Inhibitor Market Forecasts and Analysis - By Countries
10.1.6.1 Canada HDAC Inhibitor Market
10.1.6.1.1 Canada HDAC Inhibitor Market by Class
10.1.6.1.2 Canada HDAC Inhibitor Market by Applications
10.1.6.1.3 Canada HDAC Inhibitor Market by End User
10.1.6.2 Mexico HDAC Inhibitor Market
10.1.6.2.1 Mexico HDAC Inhibitor Market by Class
10.1.6.2.2 Mexico HDAC Inhibitor Market by Applications
10.1.6.2.3 Mexico HDAC Inhibitor Market by End User
10.1.6.3 US HDAC Inhibitor Market
10.1.6.3.1 US HDAC Inhibitor Market by Class
10.1.6.3.2 US HDAC Inhibitor Market by Applications
10.1.6.3.3 US HDAC Inhibitor Market by End User
10.2. EUROPE
10.2.1 Europe HDAC Inhibitor Market Overview
10.2.2 Europe HDAC Inhibitor Market Forecasts and Analysis
10.2.3 Europe HDAC Inhibitor Market Forecasts and Analysis - By Class
10.2.4 Europe HDAC Inhibitor Market Forecasts and Analysis - By Applications
10.2.5 Europe HDAC Inhibitor Market Forecasts and Analysis - By End User
10.2.6 Europe HDAC Inhibitor Market Forecasts and Analysis - By Countries
10.2.6.1 Germany HDAC Inhibitor Market
10.2.6.1.1 Germany HDAC Inhibitor Market by Class
10.2.6.1.2 Germany HDAC Inhibitor Market by Applications
10.2.6.1.3 Germany HDAC Inhibitor Market by End User
10.2.6.2 France HDAC Inhibitor Market
10.2.6.2.1 France HDAC Inhibitor Market by Class
10.2.6.2.2 France HDAC Inhibitor Market by Applications
10.2.6.2.3 France HDAC Inhibitor Market by End User
10.2.6.3 Italy HDAC Inhibitor Market
10.2.6.3.1 Italy HDAC Inhibitor Market by Class
10.2.6.3.2 Italy HDAC Inhibitor Market by Applications
10.2.6.3.3 Italy HDAC Inhibitor Market by End User
10.2.6.4 Spain HDAC Inhibitor Market
10.2.6.4.1 Spain HDAC Inhibitor Market by Class
10.2.6.4.2 Spain HDAC Inhibitor Market by Applications
10.2.6.4.3 Spain HDAC Inhibitor Market by End User
10.2.6.5 United Kingdom HDAC Inhibitor Market
10.2.6.5.1 United Kingdom HDAC Inhibitor Market by Class
10.2.6.5.2 United Kingdom HDAC Inhibitor Market by Applications
10.2.6.5.3 United Kingdom HDAC Inhibitor Market by End User
10.2.6.6 Rest of Europe HDAC Inhibitor Market
10.2.6.6.1 Rest of Europe HDAC Inhibitor Market by Class
10.2.6.6.2 Rest of Europe HDAC Inhibitor Market by Applications
10.2.6.6.3 Rest of Europe HDAC Inhibitor Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific HDAC Inhibitor Market Overview
10.3.2 Asia-Pacific HDAC Inhibitor Market Forecasts and Analysis
10.3.3 Asia-Pacific HDAC Inhibitor Market Forecasts and Analysis - By Class
10.3.4 Asia-Pacific HDAC Inhibitor Market Forecasts and Analysis - By Applications
10.3.5 Asia-Pacific HDAC Inhibitor Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific HDAC Inhibitor Market Forecasts and Analysis - By Countries
10.3.6.1 Australia HDAC Inhibitor Market
10.3.6.1.1 Australia HDAC Inhibitor Market by Class
10.3.6.1.2 Australia HDAC Inhibitor Market by Applications
10.3.6.1.3 Australia HDAC Inhibitor Market by End User
10.3.6.2 China HDAC Inhibitor Market
10.3.6.2.1 China HDAC Inhibitor Market by Class
10.3.6.2.2 China HDAC Inhibitor Market by Applications
10.3.6.2.3 China HDAC Inhibitor Market by End User
10.3.6.3 India HDAC Inhibitor Market
10.3.6.3.1 India HDAC Inhibitor Market by Class
10.3.6.3.2 India HDAC Inhibitor Market by Applications
10.3.6.3.3 India HDAC Inhibitor Market by End User
10.3.6.4 Japan HDAC Inhibitor Market
10.3.6.4.1 Japan HDAC Inhibitor Market by Class
10.3.6.4.2 Japan HDAC Inhibitor Market by Applications
10.3.6.4.3 Japan HDAC Inhibitor Market by End User
10.3.6.5 South Korea HDAC Inhibitor Market
10.3.6.5.1 South Korea HDAC Inhibitor Market by Class
10.3.6.5.2 South Korea HDAC Inhibitor Market by Applications
10.3.6.5.3 South Korea HDAC Inhibitor Market by End User
10.3.6.6 Rest of Asia-Pacific HDAC Inhibitor Market
10.3.6.6.1 Rest of Asia-Pacific HDAC Inhibitor Market by Class
10.3.6.6.2 Rest of Asia-Pacific HDAC Inhibitor Market by Applications
10.3.6.6.3 Rest of Asia-Pacific HDAC Inhibitor Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa HDAC Inhibitor Market Overview
10.4.2 Middle East and Africa HDAC Inhibitor Market Forecasts and Analysis
10.4.3 Middle East and Africa HDAC Inhibitor Market Forecasts and Analysis - By Class
10.4.4 Middle East and Africa HDAC Inhibitor Market Forecasts and Analysis - By Applications
10.4.5 Middle East and Africa HDAC Inhibitor Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa HDAC Inhibitor Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa HDAC Inhibitor Market
10.4.6.1.1 South Africa HDAC Inhibitor Market by Class
10.4.6.1.2 South Africa HDAC Inhibitor Market by Applications
10.4.6.1.3 South Africa HDAC Inhibitor Market by End User
10.4.6.2 Saudi Arabia HDAC Inhibitor Market
10.4.6.2.1 Saudi Arabia HDAC Inhibitor Market by Class
10.4.6.2.2 Saudi Arabia HDAC Inhibitor Market by Applications
10.4.6.2.3 Saudi Arabia HDAC Inhibitor Market by End User
10.4.6.3 U.A.E HDAC Inhibitor Market
10.4.6.3.1 U.A.E HDAC Inhibitor Market by Class
10.4.6.3.2 U.A.E HDAC Inhibitor Market by Applications
10.4.6.3.3 U.A.E HDAC Inhibitor Market by End User
10.4.6.4 Rest of Middle East and Africa HDAC Inhibitor Market
10.4.6.4.1 Rest of Middle East and Africa HDAC Inhibitor Market by Class
10.4.6.4.2 Rest of Middle East and Africa HDAC Inhibitor Market by Applications
10.4.6.4.3 Rest of Middle East and Africa HDAC Inhibitor Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America HDAC Inhibitor Market Overview
10.5.2 South and Central America HDAC Inhibitor Market Forecasts and Analysis
10.5.3 South and Central America HDAC Inhibitor Market Forecasts and Analysis - By Class
10.5.4 South and Central America HDAC Inhibitor Market Forecasts and Analysis - By Applications
10.5.5 South and Central America HDAC Inhibitor Market Forecasts and Analysis - By End User
10.5.6 South and Central America HDAC Inhibitor Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil HDAC Inhibitor Market
10.5.6.1.1 Brazil HDAC Inhibitor Market by Class
10.5.6.1.2 Brazil HDAC Inhibitor Market by Applications
10.5.6.1.3 Brazil HDAC Inhibitor Market by End User
10.5.6.2 Argentina HDAC Inhibitor Market
10.5.6.2.1 Argentina HDAC Inhibitor Market by Class
10.5.6.2.2 Argentina HDAC Inhibitor Market by Applications
10.5.6.2.3 Argentina HDAC Inhibitor Market by End User
10.5.6.3 Rest of South and Central America HDAC Inhibitor Market
10.5.6.3.1 Rest of South and Central America HDAC Inhibitor Market by Class
10.5.6.3.2 Rest of South and Central America HDAC Inhibitor Market by Applications
10.5.6.3.3 Rest of South and Central America HDAC Inhibitor Market by End User

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. HDAC INHIBITOR MARKET, KEY COMPANY PROFILES
12.1. CELLERON THERAPEUTICS
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. CELGENE CORPORATION
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NOVARTIS
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. EISAI CO., LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. MERCK AND CO., INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. PFIZER INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ACETYLON PHARMACEUTICALS, INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ASTRAZENECA PLC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. CHIPSCREEN BIOSCIENCES
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. CHROMA THERAPEUTICS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1.Celleron Therapeutics
2.Celgene Corporation
3.Novartis
4.Eisai Co., Ltd
5.Merck and Co., Inc.
6.Pfizer Inc.
7.Acetylon Pharmaceuticals, Inc.
8.AstraZeneca plc.
9.Chipscreen Biosciences
10.Chroma Therapeutics
TIPRE00023439
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.